[1] In a 12 week randomised clinical trial, subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving placebo
Individuals with conditions like coeliac disease or Crohns disease, which can limit B12 absorption from food, may particularly benefit from B12 injections
Reference: Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (2021)
Semaglutide, the latter has a clinically tested dosage
Any therapeutic use occurs under physician supervision as off-label research application requiring comprehensive informed consent, medical monitoring, and understanding that the peptide is not an approved pharmaceutical agent
The GLP-1 drops administration guide covers alternative delivery methods for those who prefer non-injection routes